{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T11:33:26Z","timestamp":1771846406254,"version":"3.50.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009619","name":"japan agency for medical research and development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s12032-021-01602-x","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T20:30:02Z","timestamp":1636576202000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Nicaraven prevents the fast growth of inflamed tumors by an anti-inflammatory mechanism"],"prefix":"10.1007","volume":"39","author":[{"given":"Lina","family":"Abdelghany","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nageh","family":"El-Mahdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Jingu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7653-8873","authenticated-orcid":false,"given":"Tao-Sheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"key":"1602_CR1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026781","author":"E Hirata","year":"2017","unstructured":"Hirata E, Sahai E. Tumor microenvironment and differential responses to therapy. Cold Spring Harb Perspect Med. 2017. https:\/\/doi.org\/10.1101\/cshperspect.a026781.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1602_CR2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","volume":"21","author":"D Hanahan","year":"2012","unstructured":"Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309\u201322. https:\/\/doi.org\/10.1016\/j.ccr.2012.02.022.","journal-title":"Cancer Cell"},{"key":"1602_CR3","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/jcb.21159","volume":"815","author":"H Li","year":"2007","unstructured":"Li H, Fan X, Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem. 2007;815:805\u201315. https:\/\/doi.org\/10.1002\/jcb.21159.","journal-title":"J Cell Biochem"},{"key":"1602_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ccr.2005.05.024","volume":"7","author":"JA Joyce","year":"2005","unstructured":"Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell. 2005;7:513\u201320. https:\/\/doi.org\/10.1016\/j.ccr.2005.05.024.","journal-title":"Cancer Cell"},{"key":"1602_CR5","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436\u201344. https:\/\/doi.org\/10.1038\/nature07205.","journal-title":"Nature"},{"key":"1602_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.semcancer.2004.06.006","volume":"14","author":"M Philip","year":"2004","unstructured":"Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004;14:433\u20139. https:\/\/doi.org\/10.1016\/j.semcancer.2004.06.006.","journal-title":"Semin Cancer Biol"},{"key":"1602_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/983698","author":"E Uribe-Querol","year":"2015","unstructured":"Uribe-Querol E, Rosales C. Neutrophils in cancer: two sides of the same coin. J Immunol Res. 2015. https:\/\/doi.org\/10.1155\/2015\/983698.","journal-title":"J Immunol Res"},{"key":"1602_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6058147","author":"J Kim","year":"2016","unstructured":"Kim J, Bae JS. Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediators Inflamm. 2016. https:\/\/doi.org\/10.1155\/2016\/6058147.","journal-title":"Mediators Inflamm"},{"key":"1602_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-52956-2","volume":"9","author":"WMT Kuwabara","year":"2019","unstructured":"Kuwabara WMT, Andrade-Silva J, Pereira JNB, et al. Neutrophil activation causes tumor regression in Walker 256 tumor-bearing rats. Sci Rep. 2019;9:1\u201315. https:\/\/doi.org\/10.1038\/s41598-019-52956-2.","journal-title":"Sci Rep"},{"key":"1602_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0610-4","volume":"7","author":"C Lee","year":"2019","unstructured":"Lee C, Jeong H, Bae Y, et al. Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide. J Immunother Cancer. 2019;7:1\u201314. https:\/\/doi.org\/10.1186\/s40425-019-0610-4.","journal-title":"J Immunother Cancer"},{"key":"1602_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2019.01512","volume":"9","author":"SD Jayasingam","year":"2020","unstructured":"Jayasingam SD, Citartan M, Thang TH, et al. Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue: technicalities and challenges in routine clinical practice. Front Oncol. 2020;9:1\u20139. https:\/\/doi.org\/10.3389\/fonc.2019.01512.","journal-title":"Front Oncol"},{"key":"1602_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.bbcan.2017.10.007","volume":"1869","author":"M Santoni","year":"2018","unstructured":"Santoni M, Romagnoli E, Saladino T, et al. Triple negative breast cancer: key role of tumor-associated macrophages in regulating the activity of anti-PD-1\/PD-L1 agents. Biochim Biophys Acta - Rev Cancer. 2018;1869:78\u201384. https:\/\/doi.org\/10.1016\/j.bbcan.2017.10.007.","journal-title":"Biochim Biophys Acta - Rev Cancer"},{"key":"1602_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.00792","volume":"10","author":"Y Yao","year":"2019","unstructured":"Yao Y, Xu XH, Jin L. Macrophage polarization in physiological and pathological pregnancy. Front Immunol. 2019;10:1\u201313. https:\/\/doi.org\/10.3389\/fimmu.2019.00792.","journal-title":"Front Immunol"},{"key":"1602_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.trsl.2017.11.002","volume":"191","author":"X Shi","year":"2018","unstructured":"Shi X, Shiao SL. The role of macrophage phenotype in regulating the response to radiation therapy. Transl Res. 2018;191:64\u201380. https:\/\/doi.org\/10.1016\/j.trsl.2017.11.002.","journal-title":"Transl Res"},{"key":"1602_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BSR20171555","volume":"38","author":"HL Lu","year":"2018","unstructured":"Lu HL, Huang XY, Luo YF, et al. Activation of M1 macrophages plays a critical role in the initiation of acute lung injury. Biosci Rep. 2018;38:1\u201313. https:\/\/doi.org\/10.1042\/BSR20171555.","journal-title":"Biosci Rep"},{"key":"1602_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0060023","volume":"8","author":"M Kawakatsu","year":"2013","unstructured":"Kawakatsu M, Urata Y, Imai R, et al. Nicaraven attenuates radiation-induced injury in hematopoietic stem\/progenitor cells in mice. PLoS ONE. 2013;8:1\u20137. https:\/\/doi.org\/10.1371\/journal.pone.0060023.","journal-title":"PLoS ONE"},{"key":"1602_CR17","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-08076-2","author":"X Zhang","year":"2019","unstructured":"Zhang X, Moriwaki T, Kawabata T, et al. Nicaraven attenuates postoperative systemic inflammatory responses-induced tumor metastasis. Ann Surg Oncol. 2019. https:\/\/doi.org\/10.1245\/s10434-019-08076-2.","journal-title":"Ann Surg Oncol"},{"key":"1602_CR18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.canlet.2018.01.037","volume":"418","author":"C Yan","year":"2018","unstructured":"Yan C, Luo L, Urata Y, et al. Nicaraven reduces cancer metastasis to irradiated lungs by decreasing CCL8 and macrophage recruitment. Cancer Lett. 2018;418:204\u201310. https:\/\/doi.org\/10.1016\/j.canlet.2018.01.037.","journal-title":"Cancer Lett"},{"key":"1602_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11095-013-1134-0","volume":"31","author":"Q Li","year":"2014","unstructured":"Li Q, Shu Y. Pharmacological modulation of cytotoxicity and cellular uptake of anti-cancer drugs by PDE5 inhibitors in lung cancer cells. Pharm Res. 2014;31:86\u201396. https:\/\/doi.org\/10.1007\/s11095-013-1134-0.","journal-title":"Pharm Res"},{"key":"1602_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cytogfr.2011.06.001","volume":"22","author":"M Liu","year":"2011","unstructured":"Liu M, Guo S, Hibbert JM, et al. CXCL10\/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 2011;22:121\u201330. https:\/\/doi.org\/10.1016\/j.cytogfr.2011.06.001.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1602_CR21","doi-asserted-by":"publisher","first-page":"8148","DOI":"10.4049\/jimmunol.178.12.8148","volume":"178","author":"JM Petty","year":"2007","unstructured":"Petty JM, Sueblinvong V, Lenox CC, et al. Pulmonary stromal-derived factor-1 expression and effect on neutrophil recruitment during acute lung injury. J Immunol. 2007;178:8148\u201357. https:\/\/doi.org\/10.4049\/jimmunol.178.12.8148.","journal-title":"J Immunol"},{"key":"1602_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1182\/blood-2009-12-258186.The","volume":"117","author":"L Sa","year":"2015","unstructured":"Sa L, Estecha A, Samaniego R, et al. The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood. 2015;117:88\u201398. https:\/\/doi.org\/10.1182\/blood-2009-12-258186.The.","journal-title":"Blood"},{"key":"1602_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0378-4274(99)00282-9","volume":"112\u2013113","author":"KE Driscoll","year":"2000","unstructured":"Driscoll KE. TNF\u03b1 and MIP-2: role in particle-induced inflammation and regulation by oxidative stress. Toxicol Lett. 2000;112\u2013113:177\u201383.","journal-title":"Toxicol Lett"},{"key":"1602_CR24","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.4049\/jimmunol.167.8.4635","volume":"167","author":"SP Matzer","year":"2001","unstructured":"Matzer SP, Baumann T, Lukacs NW, et al. Constitutive expression of macrophage-inflammatory protein 2 (MIP-2) mRNA in bone marrow gives rise to peripheral neutrophils with preformed MIP-2 protein. J Immunol. 2001;167:4635\u201343. https:\/\/doi.org\/10.4049\/jimmunol.167.8.4635.","journal-title":"J Immunol"},{"key":"1602_CR25","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.3748\/wjg.v23.i17.3043","volume":"23","author":"CC Qin","year":"2017","unstructured":"Qin CC, Liu YN, Hu Y, et al. Macrophage inflammatory protein-2 as mediator of inflammation in acute liver injury. World J Gastroenterol. 2017;23:3043\u201352. https:\/\/doi.org\/10.3748\/wjg.v23.i17.3043.","journal-title":"World J Gastroenterol"},{"key":"1602_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2016.1163462","volume":"5","author":"T Jiang","year":"2016","unstructured":"Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016;5:1\u201310. https:\/\/doi.org\/10.1080\/2162402X.2016.1163462.","journal-title":"Oncoimmunology"},{"key":"1602_CR27","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.4049\/jimmunol.172.7.3983","volume":"172","author":"BH Nelson","year":"2004","unstructured":"Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol. 2004;172:3983\u20138. https:\/\/doi.org\/10.4049\/jimmunol.172.7.3983.","journal-title":"J Immunol"},{"key":"1602_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.20191247","volume":"217","author":"JG Pol","year":"2020","unstructured":"Pol JG, Caudana P, Paillet J, et al. Effects of interleukin-2 in immunostimulation and immunosuppression. J Exp Med. 2020;217:1\u201315. https:\/\/doi.org\/10.1084\/jem.20191247.","journal-title":"J Exp Med"},{"key":"1602_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020392","author":"J Y\u00e9lamos","year":"2020","unstructured":"Y\u00e9lamos J, Moreno-Lama L, Jimeno J, Ali SO. Immunomodulatory roles of PARP-1 and PARP-2: impact on PARP-centered cancer therapies. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12020392.","journal-title":"Cancers (Basel)"},{"key":"1602_CR30","doi-asserted-by":"publisher","first-page":"384","DOI":"10.5306\/wjco.v2.i12.384","volume":"2","author":"A Azevedo","year":"2011","unstructured":"Azevedo A. IL-6\/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol. 2011;2:384. https:\/\/doi.org\/10.5306\/wjco.v2.i12.384.","journal-title":"World J Clin Oncol"},{"key":"1602_CR31","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1038\/sj.bjc.6601814","volume":"90","author":"V Michalaki","year":"2004","unstructured":"Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-\u03b1 correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer. 2004;90:2312\u20136. https:\/\/doi.org\/10.1038\/sj.bjc.6601814.","journal-title":"Br J Cancer"},{"key":"1602_CR32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1046\/j.1525-1438.2003.13197.x","volume":"13","author":"R Srivani","year":"2003","unstructured":"Srivani R, Nagarajan B. A prognostic insight on in vivo expression of interleukin-6 in uterine cervical cancer. Int J Gynecol cancer Off J Int Gynecol Cancer Soc. 2003;13:331\u20139. https:\/\/doi.org\/10.1046\/j.1525-1438.2003.13197.x.","journal-title":"Int J Gynecol cancer Off J Int Gynecol Cancer Soc"},{"key":"1602_CR33","first-page":"513","volume":"15","author":"CC Tsai","year":"1999","unstructured":"Tsai CC, Chen CC, Lin CC, et al. Interleukin-1 beta in oral submucous fibrosis, verrucous hyperplasia and squamous cell carcinoma tissues. Kaohsiung J Med Sci. 1999;15:513\u20139.","journal-title":"Kaohsiung J Med Sci"},{"key":"1602_CR34","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.3748\/wjg.v13.i11.1747","volume":"13","author":"Z-B Ye","year":"2007","unstructured":"Ye Z-B, Ma T, Li H, et al. Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol. 2007;13:1747\u201351. https:\/\/doi.org\/10.3748\/wjg.v13.i11.1747.","journal-title":"World J Gastroenterol"},{"key":"1602_CR35","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860\u20137. https:\/\/doi.org\/10.1038\/nature01322.","journal-title":"Nature"},{"key":"1602_CR36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.semcancer.2005.07.006","volume":"16","author":"A Ben-Baruch","year":"2006","unstructured":"Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol. 2006;16:38\u201352. https:\/\/doi.org\/10.1016\/j.semcancer.2005.07.006.","journal-title":"Semin Cancer Biol"},{"key":"1602_CR37","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.7150\/ijbs.25720","volume":"14","author":"S Guo","year":"2018","unstructured":"Guo S, Deng CX. Effect of stromal cells in tumor microenvironment on metastasis initiation. Int J Biol Sci. 2018;14:2083\u201393. https:\/\/doi.org\/10.7150\/ijbs.25720.","journal-title":"Int J Biol Sci"},{"key":"1602_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4255\/mcpharmacol.09.05","volume":"1","author":"ER Rayburn","year":"2009","unstructured":"Rayburn ER, Ezell SJ, Zhang R. Anti-inflammatory agents for cancer therapy. Mol Cell Pharmacol. 2009;1:29\u201343. https:\/\/doi.org\/10.4255\/mcpharmacol.09.05.","journal-title":"Mol Cell Pharmacol"},{"key":"1602_CR39","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/jnci\/djk200","volume":"99","author":"A Bardia","year":"2007","unstructured":"Bardia A, Ebbert JO, Vierkant RA, et al. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst. 2007;99:881\u20139. https:\/\/doi.org\/10.1093\/jnci\/djk200.","journal-title":"J Natl Cancer Inst"},{"key":"1602_CR40","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0140-6736(07)60747-8","volume":"369","author":"E Flossmann","year":"2007","unstructured":"Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet (London, England). 2007;369:1603\u201313. https:\/\/doi.org\/10.1016\/S0140-6736(07)60747-8.","journal-title":"Lancet (London, England)"},{"key":"1602_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s1054-3589(08)60067-8","volume":"39","author":"WE Smalley","year":"1997","unstructured":"Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol. 1997;39:1\u201320. https:\/\/doi.org\/10.1016\/s1054-3589(08)60067-8.","journal-title":"Adv Pharmacol"},{"key":"1602_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1053\/j.seminoncol.2004.03.042","volume":"31","author":"B Arun","year":"2004","unstructured":"Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol. 2004;31:22\u20139. https:\/\/doi.org\/10.1053\/j.seminoncol.2004.03.042.","journal-title":"Semin Oncol"},{"key":"1602_CR43","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ygyno.2006.03.036","volume":"103","author":"JH Farley","year":"2006","unstructured":"Farley JH, Truong V, Goo E, et al. A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor Celecoxib in the treatment of cervical dysplasia. Gynecol Oncol. 2006;103:425\u201330. https:\/\/doi.org\/10.1016\/j.ygyno.2006.03.036.","journal-title":"Gynecol Oncol"},{"key":"1602_CR44","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1158\/1078-0432.ccr-0829-3","volume":"10","author":"H Wang","year":"2004","unstructured":"Wang H, Li M, Rinehart JJ, Zhang R. Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin cancer Res an Off J Am Assoc Cancer Res. 2004;10:1633\u201344. https:\/\/doi.org\/10.1158\/1078-0432.ccr-0829-3.","journal-title":"Clin cancer Res an Off J Am Assoc Cancer Res"},{"key":"1602_CR45","first-page":"947","volume":"30","author":"H Wang","year":"2007","unstructured":"Wang H, Wang Y, Rayburn ER, et al. Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. Int J Oncol. 2007;30:947\u201353.","journal-title":"Int J Oncol"},{"key":"1602_CR46","doi-asserted-by":"publisher","DOI":"10.1139\/cjpp-2020-0558","author":"H Lin","year":"2020","unstructured":"Lin H, Wu X, Yang Y, et al. Nicaraven inhibits TNF\u03b1-induced endothelial activation and inflammation through suppressing NF-\u03baB signaling pathway. Can J Physiol Pharmacol. 2020. https:\/\/doi.org\/10.1139\/cjpp-2020-0558.","journal-title":"Can J Physiol Pharmacol"},{"key":"1602_CR47","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","volume":"102","author":"P Workman","year":"2010","unstructured":"Workman P, Aboagye EO, Balkwill F, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102:1555\u201377. https:\/\/doi.org\/10.1038\/sj.bjc.6605642.","journal-title":"Br J Cancer"},{"key":"1602_CR48","first-page":"1","volume-title":"Inflammation and cancer","author":"M Gomes","year":"2014","unstructured":"Gomes M, Teixeira AL, Coelho A, et al. The role of inflammation in lung cancer. In: Aggarwal BB, Sung B, Gupta SC, editors., et al., Inflammation and cancer. Basel: Springer; 2014. p. 1\u201323."},{"key":"1602_CR49","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1016\/0006-2952(86)90385-0","volume":"35","author":"DG Kennedy","year":"1986","unstructured":"Kennedy DG, Van den Berg HW, Clarke R, Murphy RF. Enhancement of methotrexate cytotoxicity towards the MDA.MB.436 human breast cancer cell line by dipyridamole: the role of methotrexate polyglutamates. Biochem Pharmacol. 1986;35:3053\u20136. https:\/\/doi.org\/10.1016\/0006-2952(86)90385-0.","journal-title":"Biochem Pharmacol"},{"key":"1602_CR50","doi-asserted-by":"publisher","first-page":"4788","DOI":"10.1038\/s41388-019-0758-x","volume":"38","author":"A Schwiebs","year":"2019","unstructured":"Schwiebs A, Herrero San Juan M, Schmidt KG, et al. Cancer-induced inflammation and inflammation-induced cancer in colon: a role for S1P lyase. Oncogene. 2019;38:4788\u2013803. https:\/\/doi.org\/10.1038\/s41388-019-0758-x.","journal-title":"Oncogene"},{"key":"1602_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0098259","volume":"9","author":"M Shen","year":"2014","unstructured":"Shen M, Hu P, Donskov F, et al. Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis. PLoS ONE. 2014;9:1\u201310. https:\/\/doi.org\/10.1371\/journal.pone.0098259.","journal-title":"PLoS ONE"},{"key":"1602_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2019.01146","volume":"9","author":"MT Masucci","year":"2019","unstructured":"Masucci MT, Minopoli M, Carriero MV. Tumor associated neutrophils. Their role in tumorigenesis, metastasis, prognosis and therapy. Front Oncol. 2019;9:1\u201316. https:\/\/doi.org\/10.3389\/fonc.2019.01146.","journal-title":"Front Oncol"},{"key":"1602_CR53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.21873\/invivo.11459","volume":"33","author":"K Nakamatsu","year":"2019","unstructured":"Nakamatsu K, Anami S, Fukuda K, et al. Neutrophil-to-lymphocyte ratio predicts survival after whole-brain radiotherapy in non-small cell lung cancer. In Vivo (Brooklyn). 2019;33:195\u2013201. https:\/\/doi.org\/10.21873\/invivo.11459.","journal-title":"In Vivo (Brooklyn)"},{"key":"1602_CR54","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/701067","author":"Z Granot","year":"2015","unstructured":"Granot Z, Jablonska J. Distinct functions of neutrophil in cancer and its regulation. Mediators Inflamm. 2015. https:\/\/doi.org\/10.1155\/2015\/701067.","journal-title":"Mediators Inflamm"},{"key":"1602_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11040564","author":"L Wu","year":"2019","unstructured":"Wu L, Saxena S, Awaji M, Singh RK. Tumor-associated neutrophils in cancer: going pro. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11040564.","journal-title":"Cancers (Basel)"},{"key":"1602_CR56","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00281-013-0367-7","volume":"35","author":"SK Biswas","year":"2013","unstructured":"Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol. 2013;35:585\u2013600. https:\/\/doi.org\/10.1007\/s00281-013-0367-7.","journal-title":"Semin Immunopathol"},{"key":"1602_CR57","doi-asserted-by":"publisher","first-page":"8917804","DOI":"10.1155\/2018\/8917804","volume":"2018","author":"L Parisi","year":"2018","unstructured":"Parisi L, Gini E, Baci D, et al. Macrophage polarization in chronic inflammatory diseases: killers or builders? J Immunol Res. 2018;2018:8917804. https:\/\/doi.org\/10.1155\/2018\/8917804.","journal-title":"J Immunol Res"},{"key":"1602_CR58","first-page":"4625","volume":"56","author":"RD Leek","year":"1996","unstructured":"Leek RD, Lewis CE, Whitehouse R, et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996;56:4625\u20139.","journal-title":"Cancer Res"},{"key":"1602_CR59","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1084\/jem.20150295","volume":"212","author":"A Mantovani","year":"2015","unstructured":"Mantovani A, Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med. 2015;212:435\u201345. https:\/\/doi.org\/10.1084\/jem.20150295.","journal-title":"J Exp Med"},{"key":"1602_CR60","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399\u2013416. https:\/\/doi.org\/10.1038\/nrclinonc.2016.217.","journal-title":"Nat Rev Clin Oncol"},{"key":"1602_CR61","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4048\/jbc.2019.22.e5","volume":"22","author":"H Jeong","year":"2019","unstructured":"Jeong H, Hwang I, Kang SH, et al. Tumor-associated macrophages as potential prognostic biomarkers of invasive breast cancer. J Breast Cancer. 2019;22:38\u201351. https:\/\/doi.org\/10.4048\/jbc.2019.22.e5.","journal-title":"J Breast Cancer"},{"key":"1602_CR62","doi-asserted-by":"publisher","first-page":"16554","DOI":"10.1038\/s41598-020-73624-w","volume":"10","author":"M Oshi","year":"2020","unstructured":"Oshi M, Tokumaru Y, Asaoka M, et al. M1 Macrophage and M1\/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer. Sci Rep. 2020;10:16554. https:\/\/doi.org\/10.1038\/s41598-020-73624-w.","journal-title":"Sci Rep"},{"key":"1602_CR63","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.2174\/092986707780597998","volume":"14","author":"R Aguilar-Quesada","year":"2007","unstructured":"Aguilar-Quesada R, Munoz-Gamez JA, Martin-Oliva D, et al. Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation. Curr Med Chem. 2007;14:1179\u201387.","journal-title":"Curr Med Chem"},{"key":"1602_CR64","doi-asserted-by":"crossref","unstructured":"Szab\u00f3 BC, Lim LHK, Cuzzocrea S, et al. (1997) Antiinflammatory effects. 186.","DOI":"10.1084\/jem.186.7.1041"},{"key":"1602_CR65","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.it.2011.08.006","volume":"32","author":"EC Thompson","year":"2011","unstructured":"Thompson EC. Innate immune cells in motion. Trends Immunol. 2011;32:451. https:\/\/doi.org\/10.1016\/j.it.2011.08.006.","journal-title":"Trends Immunol"},{"key":"1602_CR66","first-page":"3421","volume":"26","author":"M Watanabe","year":"2006","unstructured":"Watanabe M, Akiyama N, Sekine H, et al. Inhibition of poly (ADP-ribose) polymerase as a protective effect of nicaraven in ionizing radiation- and ara-C-induced cell death. Anticancer Res. 2006;26:3421\u20137.","journal-title":"Anticancer Res"},{"key":"1602_CR67","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cyto.2009.08.002","volume":"48","author":"G Huang","year":"2009","unstructured":"Huang G, Shi LZ, Chi H. Regulation of JNK and p38 MAPK in the immune system: signal integration, propagation and termination. Cytokine. 2009;48:161\u20139. https:\/\/doi.org\/10.1016\/j.cyto.2009.08.002.","journal-title":"Cytokine"},{"key":"1602_CR68","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.116392","author":"FR Balkwill","year":"2012","unstructured":"Balkwill FR, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012. https:\/\/doi.org\/10.1242\/jcs.116392.","journal-title":"J Cell Sci"},{"key":"1602_CR69","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1248\/cpb.48.467","volume":"48","author":"T Akimoto","year":"2000","unstructured":"Akimoto T. Quantitative analysis of the kinetic constant of the reaction of N, N\u2019- propylenedinicotinamide with the hydroxyl radical using dimethyl sulfoxide and deduction of its structure in chloroform. Chem Pharm Bull. 2000;48:467\u201376. https:\/\/doi.org\/10.1248\/cpb.48.467.","journal-title":"Chem Pharm Bull"},{"key":"1602_CR70","doi-asserted-by":"publisher","first-page":"L1018","DOI":"10.1152\/ajplung.00086.2006","volume":"291","author":"M Zhao","year":"2006","unstructured":"Zhao M, Fernandez LG, Doctor A, et al. Alveolar macrophage activation is a key initiation signal for acute lung ischemia-reperfusion injury. Am J Physiol Cell Mol Physiol. 2006;291:L1018\u201326. https:\/\/doi.org\/10.1152\/ajplung.00086.2006.","journal-title":"Am J Physiol Cell Mol Physiol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01602-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-021-01602-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01602-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T07:48:07Z","timestamp":1642060087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-021-01602-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1602"],"URL":"https:\/\/doi.org\/10.1007\/s12032-021-01602-x","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,10]]},"assertion":[{"value":"13 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All experiments were approved by the Institutional Animal Care and Use Committee of Nagasaki University (No.1108120943), and animal procedures were performed following institutional and national guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"7"}}